Approval · Notice of Compliance 26734 · 2021
VIMOVO: Notice of Compliance 26734
Issued September 23, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26734
- Date
- September 23, 2021
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) following an update to the Company Core Data Sheet. Update the PM to the 2020 Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIMOVO | Not yet assigned | — |
Medicinal ingredients
- NAPROXEN 375 MG per TAB
- ESOMEPRAZOLE 20 MG per TAB
- NAPROXEN 500 MG per TAB